NFXF Blog

Browse using our topic and condition filters below the featured articles. For more detailed results, please use our Search bar at the top of the page. For webinars, please visit Webinars and Videos.

All Articles

Filter by conditon
Filter by topic
Additional Filters
November 17, 2026
02 mins read

This study highlights the knowledge and experience mothers develop while raising sons living with Fragile X syndrome. The study emphasizes recognizing family strengths and knowledge, supporting caregiver well-being, and building strong support networks.

November 16, 2026
02 mins read

Tamaro’s family is counting on us to provide the information and resources families need each day and make sure no one has to navigate Fragile X alone.

November 11, 2026
04 mins read

A team of experts reviewed recent research and shared guidance to help healthcare providers better manage FXTAS symptoms, including movement, balance, memory, and mental health challenges.

November 10, 2026
02 mins read

David’s family is counting on us to advocate for policies that make a lasting impact for the disability community.

November 4, 2026
02 mins read

A new Congress offers an opportunity to introduce lawmakers to Fragile X and advocate for research, healthcare, education, and community supports. NFXF encourages families to share their experiences through Advocacy Day in Washington, DC, on February 22–23, 2027, or by participating from home.

October 28, 2026
03 mins read

Learn about the BLOOM study for males ages 13–45 with Fragile X syndrome, including what is investigational medication, eligibility, what participation involves.

October 22, 2026
02 mins read

The study explores behavioral challenges in children living with FXS, including which behaviors commonly occur together and how they affect daily life. Learn what its findings mean for individuals and families living with Fragile X syndrome.

October 21, 2026
01 min read

Anavex Life Sciences has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for its product, blarcamesine (ANAVEX®2-73), allowing the company to move forward with plans to study the investigational medication in individuals living with Fragile X syndrome (FXS).

October 15, 2026
06 mins read

Practical strategies, sensory-friendly ideas, plus insights from NFXF community members to help keep fall enjoyable and low-stress.